Genentech: New Head of Research and Early Development – European Biotechnology

Aviv Regev will follow Michael Varney as Head of Genentech Research and Early Development (gRED) at Roche subsidiary Genentech. Varney will retire from the company at the end of July.

Aviv Regev, currently Chair of the Faculty, Core Institute Member, and member of the Executive Leadership Team of the Broad Institute of MIT and Harvard, as well as Professor of Biology at MIT and Investigator of the Howard Hughes Medical Institute, will join Genentech as the new Head of gRED and will become a member of the enlarged Corporate Executive Committee as of 1 August 2020. She will be based in South San Francisco.

In particular, Regev has pioneered assays for RNA sequencing in single-cells, machine learning algorithms for distilling biological knowledge from the resulting information, and many of the first demonstrations of how to yield foundational new insights into an extraordinarily wide range of molecular circuits, systems, and fields, including immunology, neurobiology, development, inflammatory disease, cancer, and evolution. In doing so, her work is helping to answer the most general of biological questions - how cells and their circuits function and rewire, and how these dynamics underlie health and malfunction in disease.

Aviv Regev has a Ph.D. in computational biology and Master of Science from Tel Aviv University. Through her pioneering efforts she is a leader in deciphering molecular circuits that govern cells, tissues and organs in health and their malfunction in disease.

Read more:
Genentech: New Head of Research and Early Development - European Biotechnology

The Role Of Biotechnology In Sustainable Cleaning Products – European Cleaning Journal

The first sustainable cleaning products appeared on the professional hygiene market in the early 1990s and the increase in demand for these products has led to innovation and several new technologies. Biotechnology is one of the most important, as Steve Teasdale, vice-president of scientific affairs at Innuscience explains.

The first sustainable cleaning products appeared on the professional hygiene market in the early 1990s. At the time, these technologies generally did not perform especially well and were not unanimously accepted by a generally insensitive marketplace. Since then, and with more receptive audience the demand for these products continues to grow and to the point where their use is increasingly mandated in many places.

This increase in demand for such products has in turn led to innovation and the development of several new technologies. As you would expect, some quickly disappeared while others remained on the market and continued to evolve. Biotechnology is one of the most important of these, and as market conditions evolve, it continues gaining increasingly important market awareness and share.

The list of chemical ingredients historically used in cleaning products and which are now considered undesirable, of concern or are even banned continues to grow. Given their contribution to cleaning efficacy, their removal must be compensated using new substances and/or technologies. This situation has helped to promote and encourage the technological development for alternative solutions arising from biotechnology; among other things.

It is in this context that significant efforts have been invested in to bring us to a point where it is now possible to obtain as good, or even better levels of cleaning performance using biotechnological cleaning products.

Green cleaning products which mainly used ingredients derived from biotechnological processes bacterial cultures, enzyme extracts and other bio-ingredients appeared in the late 1990s. Since then, they have become increasingly popular; with increased recognition and steady commercial growth.

Specific knowledge

The ability to develop biotech cleaning products is not universally available and requires specific technological knowledge and skills that are relatively young and unusual in the professional hygiene market. While our industry has been dominated by chemistry for decades, the arrival of biotechnology has required a significant commitment in terms of energy and resources whether it be in terms of research tools, research, performance analysis, stability assessment or at the level of standards and regulatory compliance.

The manufacture of biotech cleaning products also requires unique expertise. Manufacturing cleaning products with bio-active and/or surface active molecules requires the development of special processes, procedures and quality standards. There have been many developments in this field and the standards and processes implemented are now recognised by the scientific community (Teasdale et al., Food and Chemical Toxicology https://www.sciencedirect.com/science/article/pii/ S0278691517306270)

The evolution of biotechnologies for professional cleaning is booming. We are seeing more and more products using bio-surfactants. These are surface active molecules which are produced by microorganisms and which have unique and remarkable environmental and performance properties.

Other technologies stemming from biotechnologies are under development and already starting to be introduced on the market. This is the case with new disinfection technologies that use viruses that kill targeted microbial pathogen (bacteriophages) in a very specific way instead of disrupting the entire existing microbial flora.

The use of biotechnological cleaning products has brought cleaning to a new dimension. While traditional chemical cleaners have the ability to solubilise and/or emulsify dirt, biotech cleaning products also have the ability to break and remove dirt through hydrolysis and biodegradation. This action has the additional benefit of residual activity beyond the short period of mechanical action applied during cleaning or post-cleaning action.

This new dimension of cleaning goes towards a significant revision of the traditional foundations of the famous Sinner Circle cleaning action continues for hours beyond the application of mechanical action.

Thanks to the characteristics of their make-up and their function, biotech ingredients make it possible to develop cleaning products that are highly concentrated and contain very low concentrations of chemical ingredients (mainly surfactants) once diluted before use. It also makes it possible to achieve very high cleaning and detergency performance without having to resort to using high pH, sequestering agents, builders, solvents and other substances which contribute to increasing the pollutant load and which is the reason why traditional chemical cleaning products are harmful for the environment and cleaning staffs health.

First patent

For example, in the year 2000 the first biotechnological neutral pH degreaser for kitchen floors was patented and then marketed. This diluted degreasing solution contained less than 0.05 per cent active ingredient and degreased a kitchen floor more efficiently than a traditional alkaline degreaser containing 25 times the amount of active ingredients.

Reduction using less is the first and most effective eco-friendly cleaning approach. This products high concentration rate makes it possible, among other things, to reduce the transport and use of plastic. Its high efficiency allows for very high dilution rates reducing the amount of cleaning ingredients used.

In addition, the use of this biotech degreaser directly impacted on reducing cleaning staffs risk of having an accident. It did not lead to any increase in slipperiness on kitchen floors as can happen with alkaline chemical degreasers. Thus, this reduced the risk of slip and fall in the kitchen whilst its ensured there was no risk of skin or eye burns due to its non-corrosive classification.

Broader concept

The concept of a green cleaning product refers to cleaning products that have a lower and less harmful environmental impact than that of traditional cleaning products. Although this dimension is noble and desirable, the concept for an eco-responsible cleaning product uses a much broader concept that integrates environmental, societal and economic parameters.

In order for a cleaning product to contribute in a sustainable way to the development of our industry, it must integrate these three main axes that define the concept of sustainable development. Thus, beyond the environmental impact cleaning staffs health and wellbeing as well as the cost of use must be considered when developing new cleaning technologies.

In the previous example concerning the biotech degreasing product for kitchen floors it is clear that this products use has a direct impact on aspects which are both environmental and societal. But what about the cost of use? A cleaning product that benefits the environment and workers health cannot offer a sustainable solution if it costs more to use. However, the use of biotechnologies makes it possible to develop cleaning products that advantageously integrate the economic aspect.

Since bacterial cultures and enzymatic extracts are highly effective even at very low concentrations and considering their residual and prolonged cleansing action, biotechnological cleaning products can be diluted at very high rates while providing outstanding cleaning performance. These high dilution rates lead to high-performance cleaning solutions that have a very low cost per litre in their applicative usage.

Additionally, biotech cleaning products have the ability to reduce odours due to their mode of action and their ability to extract a greater amount of dirt from surfaces; especially those which are porous and difficult to clean. In public toilets, some odours may be generated following the passage of a user.

However, in reality the most disturbing odours are those which are permanently present and that emanate from surfaces which have accumulated water and more particularly urine. The floors near bowls and urinals are particularly prone to generating these unpleasant odours.

Solving the problem

In view of their inability to solve these problems, a number of stakeholders resort to using methods that are more or less effective and that never really solve the problem. It is common to widely distribute air fresheners to mask these odours. As a last resort, we sometimes see cleaning staff use a rotary floor scrubber and a floor stripper in an attempt to unclog the problematic surfaces with no success.

Ultimately, we have all already visited bathrooms where, in desperation, the floor had been sealed with a floor finish in order to trap smelly dirt. These solutions, which are not really solutions, are all bad for the environment, the cleaning staff and the buildings tenants.

The use of air fresheners is particularly harmful and far from being a sustainable solution. These products are essentially volatile organic compounds (VOCs) and they contribute to deteriorating indoor air quality. They also cause multiple inconveniences, discomfort and symptoms which are grouped together and recognised as the Sick Building Syndrome. In addition, these air fresheners attract bad publicity and are considered by more and more people as a pollutant and an invasive nuisance. They are frequently the subject of complaints when used unreasonably.

Now, with the help of a biotechnological all-surface toilet cleaner, it is possible to clean all surfaces, including the floors. This makes it possible to dislodge the dirt accumulated over the years, which are the main sources of bad smells. After a few days of use, bad smells gradually disappear. This approach makes it possible to better clean the floors, but above all to eliminate those air fresheners.

Conclusion

As mentioned by a famous scientist who has left a mark in our history, We cannot solve a problem by using the same approach that we had used to create it. Thus, we had and still have a desperate need for new technologies that will provide real and sustainable solutions to the environmental and societal problems associated with professional cleaning and that we are still faced with today. Biotechnology is a good example of a technological and innovative contribution in this field.

innuscience.com

More:
The Role Of Biotechnology In Sustainable Cleaning Products - European Cleaning Journal

The B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Share Price Is Down 46% So Some Shareholders Are Getting Worried – Yahoo…

B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) shareholders will doubtless be very grateful to see the share price up 54% in the last month. But that doesn't help the fact that the three year return is less impressive. In fact, the share price is down 46% in the last three years, falling well short of the market return.

Check out our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

B.R.A.I.N. Biotechnology Research and Information Network isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last three years, B.R.A.I.N. Biotechnology Research and Information Network saw its revenue grow by 19% per year, compound. That's a fairly respectable growth rate. Shareholders have endured a share price decline of 19% per year. This implies the market had higher expectations of B.R.A.I.N. Biotechnology Research and Information Network. However, that's in the past now, and it's the future is more important - and the future looks brighter (based on revenue, anyway).

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

XTRA:BNN Income Statement May 4th 2020

If you are thinking of buying or selling B.R.A.I.N. Biotechnology Research and Information Network stock, you should check out this FREE detailed report on its balance sheet.

B.R.A.I.N. Biotechnology Research and Information Network shareholders may not have made money over the last year, but their total loss of 6.2% isn't as bad as the market loss of around 6.2%. Furthermore, the stock lost shareholders 19% per year over three years, so the one-year return was better in a relative sense. It is of course not much comfort to know that the losses have slowed. Shareholders will be hoping for a proper turnaround, no doubt. It's always interesting to track share price performance over the longer term. But to understand B.R.A.I.N. Biotechnology Research and Information Network better, we need to consider many other factors. Take risks, for example - B.R.A.I.N. Biotechnology Research and Information Network has 1 warning sign we think you should be aware of.

Of course B.R.A.I.N. Biotechnology Research and Information Network may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on DE exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Continued here:
The B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Share Price Is Down 46% So Some Shareholders Are Getting Worried - Yahoo...

Does Apex Biotechnology Corp.s (TPE:1733) 20% Earnings Growth Make It An Outperformer? – Simply Wall St

Measuring Apex Biotechnology Corp.s (TSEC:1733) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, which is a powerful signal for future performance. Below, I will assess 1733s recent performance announced on 31 December 2019 and compare these figures to its historical trend and industry movements.

Check out our latest analysis for Apex Biotechnology

1733s trailing twelve-month earnings (from 31 December 2019) of NT$114m has jumped 20% compared to the previous year.

Furthermore, this one-year growth rate has exceeded its 5-year annual growth average of -28%, indicating the rate at which 1733 is growing has accelerated. Whats enabled this growth? Lets take a look at if it is merely due to industry tailwinds, or if Apex Biotechnology has experienced some company-specific growth.

In terms of returns from investment, Apex Biotechnology has fallen short of achieving a 20% return on equity (ROE), recording 6.7% instead. Furthermore, its return on assets (ROA) of 4.3% is below the TW Medical Equipment industry of 6.2%, indicating Apex Biotechnologys are utilized less efficiently. And finally, its return on capital (ROC), which also accounts for Apex Biotechnologys debt level, has declined over the past 3 years from 12% to 9.3%. This correlates with an increase in debt holding, with debt-to-equity ratio rising from 21% to 29% over the past 5 years.

Apex Biotechnologys track record can be a valuable insight into its earnings performance, but it certainly doesnt tell the whole story. Recent positive growth isnt always indicative of a continued optimistic outlook. There may be factors that are impacting the industry as a whole, thus the high industry growth rate over the same time period. You should continue to research Apex Biotechnology to get a better picture of the stock by looking at:

NB: Figures in this article are calculated using data from the trailing twelve months from 31 December 2019. This may not be consistent with full year annual report figures.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

More:
Does Apex Biotechnology Corp.s (TPE:1733) 20% Earnings Growth Make It An Outperformer? - Simply Wall St

Is Regeneron Pharmaceuticals Inc (REGN) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Regeneron Pharmaceuticals Inc (REGN) is around the top of the Biotechnology industry according to InvestorsObserver. REGN received an overall rating of 79, which means that it scores higher than 79 percent of all stocks. Regeneron Pharmaceuticals Inc also achieved a score of 93 in the Biotechnology industry, putting it above 93 percent of Biotechnology stocks. Biotechnology is ranked 10 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Regeneron Pharmaceuticals Inc (REGN) stock is down -2.87% while the S&P 500 is unmoved 0% as of 10:38 AM on Tuesday, Apr 28. REGN is lower by -$15.74 from the previous closing price of $547.52 on volume of 430,590 shares. Over the past year the S&P 500 has fallen -2.19% while REGN is up 54.52%. REGN earned $18.46 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 28.81.

To see the top 5 stocks in Biotechnology click here.

Follow this link:
Is Regeneron Pharmaceuticals Inc (REGN) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Why biotech’s goal should not be to feed the world – SynBioBeta

Its a great moment for big food, big ag, and industry to do a self reflection and analysis of, how did we arrive here? How did we arrive to a world where the folks that picked the produce out of the field dont have access and or make enough to buy the very produce that theyre picking? Rolando Perez, graduate student and volunteer at Xinampa

Biotechnology is on the precipice of changing our world forever. Using solutions always there in biology and optimizing them with technology, biotech promises to solve global issues such as carbon emissions, plastic and chemical pollution, and, of course, feeding a booming population. But to really solve the issue of food, the industry needs to revolutionize more than just biology or technology. It needs to revolutionize the way it engages local cultures and economies. It will not be an easy task, a straightforward task, or a quick task. But it can be done and the people of the world depend on it being done right.

Climate change and population growth have led to predictions that the global population will reach nearly 10 billion people by 2050. Current food production processes cant keep pace with that growth. Fearing an existential crisis, several companies have adopted a tag line that goes something like this: we will feed the world through innovative biotechnologies that are more sustainable and make healthy food more accessible. And theyve got the sustainability beat down: from leveraging microbes to feed plants and reduce toxic nitrogen run-off to improved aquaculture techniques to genetic engineering foods to be more nutritious, the possibilities for producing ever more nutritious food while using less of the Earths precious resources are boundless and already in motion.

But what, exactly, does it mean for food to be accessible in todays world?

Food desert a term used to describe areas with limited access to affordable and nutritious food is the label by which weve come to describe food accessibility today. But the term is a bit of a misnomer, says Garrett Broad, author of More Than Just Food.

It suggests theres nothing there and if food deserts are the problem, the solution sounds pretty simple: just bring [stuff] to the desert.

But is there really nothing there? According to a recent New York Times exposition on the obesity epidemic in Brazil (and in big industrys role in that), there are now more obese people in the world than underweight people. Its as if the pendulum has swung the other direction where hunger was once a very real problem as a result of access to food, period, now obesity, diabetes, and heart disease prevail as a result of access to high calorie, nutrient-poor foods. This has created a new type of malnutrition, write Andrew Jacobs and Matt Richtel, one in which a growing number of people are both overweight and undernourished.

So, continues Broad, the problem isnt food deserts [per se], the problem is really a legacy and generational disinvestment in and direct discrimination in not just food but in a variety of other arenas. [This] calls for a broader set of solutions.

Said another way, the issue of food accessibility is multi-faceted and therefore cannot be solved solely through biotechnology we must come to terms with that fact at the get go. That isnt to say biotechnology cant make the food production system as a whole better. With advances in gene editing and other technologies, we can use technology to improve the nutritional profile of food (tackling malnutrition), to enable seasonable crops to be available all year round (increasing accessibility in one sense), to remove undesired characteristics such as cherry pits (increasing accessibility in another sense), and to make food more resistant to drought, one of the biggest factors influencing a significant proportion of the world populations access to food. But none of this matters if we keep operating under our current system, which, according to Broad, bottom-lines on profit margins, not on feeding people healthily and sustainably.

The biotechnological revolution can give the food industry and low-income disadvantaged communities a chance to hit the reset button to learn from the current state of affairs and prevent the inevitable shortfall of the big promises being made by biotechnology today if we dont change the societal, political, and economic backbone of the way food is made and distributed. And according to Ana Ibarra and Rolando Perez, volunteers at Salinas Valley-based Xinampa (a bio-hub aiming to support equitable economic development, workforce development, small business incubation, and scientific literacy and education), such sea change will come from getting people from all walks of life to sit down together and talk.

From left: Steven Rhyans, Anna Ibarra-Castro, Leo Tejeda, Omar Perez, Matias Kaplan, Rolando Perez. Photo credit: Steven Rhyans

Many of the communities most affected by food inequality are disadvantaged, underrepresented cultural and ethic groups, such as the Hispanic/Latinx and indigenous populations served by Xinampa. Salinas, California, where Xinampa is based, is over 75% Hispanic or Latinx and it is this population that is the life blood of one of the richest agricultural areas in the world. Xinampa is especially passionate about teaching young people high school and college students how they can use biotechnology in their future careers and to bolster their local communities. Ibarra says that young people will be critical for speeding up the development of technologies, a crucial goal given the issues we have at a global scale to sustain human life in light of climate change, decreasing arable land. The younger generations have the ability and talent to carry this forward, she says, and I believe its crucial to start engagement at a young age.

But, Perez is careful to point out, it isnt just about reaching the young.

The work here is intergenerational, and thats really important. There has to be engagement across the whole intergenerational spectrum the bio belt could be about finding opportunities for retirees to do things in the community plant gardens that produce nutritious produce for the community, for example. The next generation is like the seventh generation. You can say seven generations in the future, seven generations in the past, or you can strategically place yourself in the middle of those seven generations; something I learned from a close friend and that has helped me understand my role as a community member and citizen of our planet.

Emphasizing culture and recognizing that the community as a whole, and in particular indigenous communities, has deep-seeded, critical knowledge about agriculture is a core value of Xinampa. Instead of feeding people the all-too-often heard script of you guys just dont know anything, youre eating unhealthy, and were here to change you, they recognize and encourage the generations of knowledge and cultural richness that will be critical for effectively governing and incorporating biotechnology into our future food systems.

What the most successful groups that work around food at the grassroots level do is they push past those scripts, and they open up some storytelling about peoples cultural histories through food, says Broad, and that allows folks to claim knowledge about food and cooking and agriculture, which makes them much more likely to have ownership in this whole conversation.

And the whole conversation must also engage policy makers, those involved in the public health care system, industry leaders essentially anyone that could be affected by biotechnology.

One of the solutions that we could employ to address these inequities is to look to the expertise of individuals in public health, policy, social welfare, or other disciplines that are exposed to issues through a different lens and can provide a different point of view, says Ibarra, adding that its important to foster interdisciplinary conversation early on. We dont want to miss something. We dont want to invest in a solution that may not be the most effective simply because you forgot to include someone in the conversation. Early engagement is how these nutritious and novel foods will be cultivated from the ground up for the benefit of everyone in society.

One of the reasons early involvement in conversation will enable effective distribution of food to everyone is rooted in money. According to Broad, one of the biggest reasons why mistrust in GMOs and how GMO foods could solve some big problems isnt because companies havent been transparent. Its because people look at the big players, the companies in charge, and see companies that havent made their lives substantively better. People recognize that priorities within the biotech industry have not necessarily always been first and foremost about feeding the world equitably and sustainably but instead about who profits from certain biotechnological developments, says Broad. This erodes trust rather than building it.

A great way to build long standing trust is to have equitable distribution of the material wealth that gets created from these innovations. Essentially, how do we think about the development of these tools in an equitable and inclusive way in terms of economic development and economic opportunity? The best way to do this is to get people involved from early on and give them an economic stake so you develop companies that people are engaged in and involved in. That would be something for entrepreneurs and communities like [SynBioBeta] to be thinking about from an early stage, as opposed to thinking about it as kind of a PR approach that comes at the very end.

Its the economy stupid, he continues. Its that classic line if people can see that their economic and social life is going to benefit from these new innovations, then theyre much more likely to be interested in supporting them and have less fear, he says.

Ibarra agrees.

There is a lot of fear around automation and AI, including in communities like ours where the fear is robots are going to come in and pick produce and there will be less jobs for our laborers, she says. But I think the opportunities deriving from biotechnology have an even greater potential. In Monterey County we have a very robust economy resulting from direct and indirect agricultural jobs, but also a significant multiplier effect. If we couple new agricultural technologies, such as automation and AI, with biotechnology in parallel, you can see this allowing communities especially rural ones to be more resilient. Its a real opportunity.

This is critical for communities like Salinas Valley, where homelessness rates in elementary schools can be as high as 50 percent. According to Ibarra, agricultural communities like Salinas are the perfect place to cultivate regenerative biotechnologies that enrich our food systems and advance public health. She and Perez imagine a future for Salinas Valley completely transformed by biotechnology rooted in racial and class equity and justice. For example, Central Coast residents could create public interest biotechnologies that emphasize community control and governance, with investment in people, infrastructure, automation, and supply-chains that extend into the community and that connect to the Valleys world-class global supply-chains. Biotechnology can also be leveraged to produce nutritious crop varieties that adapt plant morphology to make harvesting by hand easier or gene drives to combat invasive pests such as the Asian Citrus Psyllid. Animal agriculture could benefit as well, with new veterinary biotechnological tools to better care for livestock and protect them from disease. Water systems could benefit as well, from cleaning the Salinas River through mycoremediation to employing biosensors to monitor city water for pollution, pesticides, and other chemicals.

In December 2019, Golden Rice was approved for direct use in the Philippines the first Asian country to grant the controversial food approval. Some expect that the added Vitamin A present in the rice will reduce by up to 50% vitamin A deficiency, the leading cause of child mortality in the country. But, others are skeptical that the rice will be the simple solution Filipinos have been waiting for, pointing out that vitamin A deficiency is a complex problem partially rooted in culture, political economics, education, and access. In essence, Golden Rice is the perfect example of both the promise of biotechnology in agriculture and its shortcomings if we dont think critically about all sides of the issue. With up and coming companies like Pairwise Plants and others using biotechnology to produce food that is more nutritious and can be available year-round, it is critical that we heed voices like Broad, Ibarra, and Perez so that technologies that can really make a difference in how we feed the world dont meet the same fate as Golden Rice.

It is possible to feed the world with biotechnology. But its only possible if our goal isnt to feed the world, but to engage local communities, support early, equitable, and inclusive communication, and to ensure that food equity doesnt just mean that everyone can afford to buy healthy food, but that the communities producing that food have equitable economic stake. Move over, big ag its time to take biotechnology from farm to table.

Read more from the original source:
Why biotech's goal should not be to feed the world - SynBioBeta

Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 …

Shire

Nanoparticles in Biotechnology and Pharmaceuticals Market: Competitive Landscape

The last chapter of the Nanoparticles in Biotechnology and Pharmaceuticals market research report focuses exclusively on the competitive landscape. It examines the main market players. In addition to a brief overview of the business, analysts provide information on their assessment and development. The list of important products in preparation is also mentioned. The competitive landscape is analyzed by understanding the companies strategies and the initiatives they have taken in recent years to overcome intense competition.

Nanoparticles in Biotechnology and Pharmaceuticals Market: Drivers and Restraints

The report explains the drivers of the future of the Nanoparticles in Biotechnology and Pharmaceuticals market. It assesses the different forces which should have a positive impact on the whole market. Analysts have looked at investments in research and development for products and technologies, which should give players a significant boost. In addition, the researchers undertook an analysis of the evolution of consumer behavior which should have an impact on the cycles of supply and demand in the Nanoparticles in Biotechnology and Pharmaceuticals market. In this research report, changes in per capita income, improvement in the economic situation and emerging trends were examined.

The research report also explains the potential restrictions on the Nanoparticles in Biotechnology and Pharmaceuticals market. The aspects assessed are likely to hamper market growth in the near future. In addition to this assessment, it offers a list of opportunities that could prove lucrative for the entire market. Analysts offer solutions to turn threats and restrictions into successful opportunities in the years to come.

Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Segmentation

In the following chapters, analysts have examined the regional segments of the Nanoparticles in Biotechnology and Pharmaceuticals market. This gives readers a deeper insight into the global market and allows for a closer look at the elements that could determine its evolution. Countless regional aspects, such as the effects of culture, environment and government policies, which affect regional markets are highlighted.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=COD&utm_medium=007

What will the report contain?

Market Dynamics: The report contains important information on influencing factors, market drivers, challenges, opportunities and market trends as part of the market dynamics.

Global Market Forecast: Readers receive production and sales forecasts for the Nanoparticles in Biotechnology and Pharmaceuticals market, production and consumption forecasts for regional markets, production, sales and price forecasts for the Nanoparticles in Biotechnology and Pharmaceuticals market by type and consumption forecasts for the Nanoparticles in Biotechnology and Pharmaceuticals market per application.

Regional Market Analysis: It can be divided into two different sections: one for the analysis of regional production and one for the analysis of regional consumption. Here, analysts share gross margin, prices, sales, production, CAGR, and other factors that indicate the growth of all regional markets examined in the report.

Market Competition: In this section, the report provides information on the situation and trends of competition, including mergers and acquisitions and expansion, the market shares of the three or five main players and the concentration of the market. Readers could also get the production, revenue, and average price shares of manufacturers.

Key Players: The report provides company profiles for a decent number of leading players in the Nanoparticles in Biotechnology and Pharmaceuticals market. It shows your current and future market growth taking into account price, gross margin, income, production, service areas, production locations and other factors.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=COD&utm_medium=007

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/stem-cell-alopecia-treatment-market-size-growth-analysis-opportunities-business-outlook-and-forecast-to-2026/

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

Here is the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 ...

Biotechnology Faculty Lecturer Joins the BPPT Covid-19 Task Force – QS WOW News

The Atma Jaya Catholic University of Indonesia (AJCUI) is contributing to reducing the Covid-19 pandemic in Indonesia. Lecturer in the Faculty of Biotechnology and Senior Researcher at BPPT, Dr. Irvan Faizal, M.Eng., has joined the TFRIC19, as the Secretary of the Task Force and the Coordinator of the Non-PCR Rapid Diagnostic Test Sub-Task Force. Lecturer of Faculty of Engineering, Dr. Ir. Lukas, MAI, CISA, IPM., is also in the task force to offer his expertise in the field of Artificial Intelligence.

The Sub-Task Force, in which Dr. Irvan is the coordinator-of, will produce a Rapid Diagnostic Test for COVID 19. In collaboration with BPPT, ITB, UNPAD, UGM, and the Research and Development Department from the Ministry of Health Research, the Rapid Diagnostic Test design for antibody detection (IgG / IgM).

I partook in the team for the reason that the competencies and abilities, especially in research and innovation, I possess, might be utilized to play a role in the handling and detecting the COVID-19 in Indonesia, said Dr. Irvan.

The lecturer in the Faculty of Biotechnology also explained that in the produced of the antibodies detection, it was designed using the COVID-19 virus from Indonesian virus isolates, hence it would be more sensitive and specific for Indonesias characteristics.

Furthermore, this sub-task force will also produce detection products using a microchip that can detect antigens so that they can be used to identify virus infections after two days of infected a person.

This innovative product may be utilized to detect COVID-19 in a patient under close monitoring (PDP) and patient under observation (ODP) in the short of time (10-15 minutes). This product expected to be more sensitive and specific for Indonesians patience in comparison to imported IgG / IgM detection, which generates low-value sensitivity and specificity, explained Dr. Irvan.

As is known, BPPT has five quick mitigation plans for the COVID-19 outbreaks. These include Whole Genome COVID-19 Origin Indonesia(analysis and forming using data from infected Indonesians),Non-PCR Diagnostic Test COVID-19 (development in the form of dip-sticks and micro-chips), andPCR Diagnostic Test COVID-19 (development following the latest mutations of COVID-19).

The other plans areCOVID-19 Pandemic Facilities and Infrastructure(strengthening suggestions and detection targets, mobile labs, health logistics, and innovation ecosystems), andArtificial Intelligence COVID-19(information technology and AI application to support diagnose and decision making).

Dr. Irvan hopes to keep supporting all teams that have performed sustained and zealously against COVID-19 in creating products that are useful in preventing, detecting, and responding to COVID-19. He advised that the community always maintain health and continue to pray.

Please support every stakeholder who had a significant concern in developing an innovative product and in research to prevent, detect, and respond to the pandemic. Take care of your health, physical distance, and keep praying, he said.

Continue reading here:
Biotechnology Faculty Lecturer Joins the BPPT Covid-19 Task Force - QS WOW News

Puma Biotechnology Inc. [PBYI] Analyzing the PBYI using Fundamentals and Trend Analysis – The Dwinnex

Puma Biotechnology Inc. [NASDAQ: PBYI] shares went higher by 12.21% from its previous closing of 8.60, now trading at the price of $9.65, also adding 1.05 points. Is PBYI stock a buy or should you stay away?

The stock had a rather active trading session with the latest closing, by far recording 1.09 million contracts. Compared to the average trading volume of PBYI shares, the company saw a far better performance. Moreover, the stock has a 34.74M float and a 20.78% run over in the last seven days. PBYI share price has been hovering between 35.27 and 5.50 lately, and is definitely worthy of attention.

Professional stock traders oftentimes make sure they verify what some leading Wall Street voices have to say about a potential buy. Currently, in relation to Puma Biotechnology Inc. [PBYI], the latest Wall Street average recommendation we can view is from the fiscal quarter that will be ending in the month of 12/30/2019. On average, stock market experts give PBYI an Hold rating. The average 12-month price forecast for this stock is $9.65, with the high estimate being $15.00, the low estimate being $6.00 and the median estimate amounting to $13.50. This is compared to its latest closing price of $8.60.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Puma Biotechnology Inc. [PBYI] is sitting at 3.00. This is compared to 1 month ago, when its average rating was 3.00.

Keep on the lookout for this organizations next scheduled financial results, which are expected to be made public on 05/06/2020.

Now lets turn to look at profitability: with a current Operating Margin for Puma Biotechnology Inc. [PBYI] sitting at -23.30% and its Gross Margin at 86.50%, this companys Net Margin is now -27.80. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This companys Return on Total Capital is -24.14, and its Return on Invested Capital has reached -47.06. Its Return on Equity is -302.70%, and its Return on Assets is -29.10%. These metrics suggest that this Puma Biotechnology Inc. does a poor job of managing its assets, and likely wont be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organizations capital structure, Puma Biotechnology Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 688.48. Similarly, its Total Debt to Total Capital is 87.32, while its Total Debt to Total Assets stands at 51.18. Looking toward the future, this publicly-traded companys Long-Term Debt to Equity is 673.45, and its Long-Term Debt to Total Capital is 85.41.

What about valuation? This companys Enterprise Value to EBITDA is -9.35. The Enterprise Value to Sales for this firm is now 1.07, and its Total Debt to Enterprise Value stands at 0.35. Puma Biotechnology Inc. [PBYI] has a Price to Book Ratio of 19.64, a Price to Cash Flow Ratio of 15.16.

Puma Biotechnology Inc. [PBYI] has 38.22M shares outstanding, amounting to a total market cap of 368.82M. Its stock price has been found in the range of 5.50 to 35.27. At its current price, it has moved down by -72.64% from its 52-week high, and it has moved up 75.45% from its 52-week low.

This stocks Beta value is currently 1.21, which indicates that it is 9.49% more volatile that the wider market. This stocks Relative Strength Index (RSI) is at 56.30. This RSI score is good, suggesting this stock is neither overbought or oversold.

Shares of Puma Biotechnology Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this companys financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.

Read the original:
Puma Biotechnology Inc. [PBYI] Analyzing the PBYI using Fundamentals and Trend Analysis - The Dwinnex

Providence-based EpiVax collaborates on ongoing research for a COVID-19 vaccine – The Brown Daily Herald

As COVID-19 continues to spread throughout the country and the world, EpiVax, a biotechnology company based in Providence, is currently leading collaborative efforts to design a vaccine against the virus.

EpiVax has been dedicated to applying (their) tools to re-engineering therapeutic proteins and to designing new vaccines, according to their website. They are partnering with researchers from four organizations to work on the COVID-19 vaccine: Generex Biotechnology, the University of Georgia, Immunomic Therapeutics and an organization based in Belgium. Other researchers have reached out to the company to aid in collaborative efforts as well.

Bringing Potential Benefits

The candidate vaccines being developed by EpiVax are T-cell-based. Unlike other COVID-19 vaccines in the works that are B-cell-based, the T-cell vaccines do not stimulate antibodies, which are molecules created by the immune system to protect against infection. Some studies have proposed that in the case of COVID-19, antibody stimulation may exacerbate respiratory symptoms, said Katie Porter, EpiVaxs business development manager.

From studies on other coronaviruses, we have learned that often the antibodies are not long-lived, so they do not hold up their defense against invading viruses for extended periods of time as the virus evolves, said Lalit Beura, assistant professor of molecular microbiology and immunology, whose research involves T-cells. Having another arm of the immune system in the form of a T-cell-focused vaccine is helpful.

EpiVax: Starting with Sequencing

There are people who are concerned that were working with the actual virus in Providence, but that is not the case, Porter said. Rather, EpiVax is using a digital representation. After determining the viruss genome, the researchers selected the amino acid sequences that form the COVID-19 SARS-CoV-2 proteins that T-cells recognize and used a computer-based technology they developed to determine the regions of these proteins that instigate the greatest immune system response. The researchers will use these short protein segments to design vaccine candidates.

EpiVax has created three designs for the collaborators to use for their distinct, biological methods of delivering the vaccine. These designs include a set of distinct, short peptides, a string of connected peptides and a modified protein. Peptides are composed of the same molecules as proteins but are shorter. We are working with various collaborators on a daily basis to provide them with the best design options for their platform technology, Porter said. For instance, the Generex collaborators are using a set of peptides while the University of Georgia collaborators will be using the modified protein model consisting of the full viral protein.

While each of these organizations is working on their own projects, they all share a common goal of developing a vaccine. EpiVax has begun delivering its protein designs to its collaborators and optimizing the strains for their mechanism. For the company, sharing their sequencing and initial design work with collaborators who can help create an eventual vaccine is important because we have the ink, and we need to give it to someone with the pen so that together we can write, Porter said.

University of Georgia: Modifying the Protein Model

Ted Ross, director of the Center for Vaccines and Immunology, Georgia Research Alliance Eminent Scholar and professor of infectious diseases at the University of Georgia, and two other investigators at the university will engineer the modified protein sequences that EpiVax is designing. Then they will run trials in animal models mice and ferrets by infecting them with the altered peptides to determine whether they produce a better immune response than the wild type viruss proteins do. If this is the case, the researchers plan to expose these animals to SARS-CoV-2 to ensure that this potential vaccination is effective. The groups expectation is to have this data ready by the middle of this summer.

Ross and his group have also been working on developing a universal flu vaccine, a vaccine that could potentially be used for all influenza viruses without requiring constant changes. Perhaps we could use those (same) techniques to eventually create a universal coronavirus vaccine, Ross said.

Generex Biotechnology: Modifying the Peptide Model

Generex Biotechnology, another therapeutics company, is modifying the peptides provided by EpiVax. They are first synthesizing the peptides predicted by EpiVaxs analysis using their Ii-Key technology. An li-Key facilitates the attachment of a four-amino-acid-long peptide to a part of the COVID-19 virus. This technology serves as a sort of flag on the virus, providing a way to artificially activate the T-cells more quickly than would happen in a typical immune response.

The researchers plan on conducting their studies by testing the modified peptides, determined by EpiVax and optimized by Generex, using blood cells from COVID-19-recovered patients. They hope to complete these studies in three to four months prior to testing the potential vaccine in live animals and people.

It is a two-fold process, said Eric von Hofe, chief scientific officer of NuGenerex Immuno-Oncology, a subsidiary of Generex. The team will be looking for a T-cell response to these peptides, as well as the generation of antibodies. After starting and completing trials in animal models, Generex hopes to begin clinical trials with about 200 volunteers that will receive the peptide-based vaccine to determine whether this produces the desired immune response and to ensure the safety of the vaccine.

The biggest advantage is that peptides represent the minimal unit required to produce an immune response while reducing safety concerns associated with other proposed COVID-19 vaccines that are RNA- and DNA-based and have the potential to insert into a persons DNA, von Hofe said. But none of these types of vaccines have been approved yet for the treatment of infectious diseases, he added.

Fundamentals of Funding

Despite the preliminary successes the companies have seen thus far, funding remains a critical part of the picture. Funding often pushes back the timeline, or worse, cancels hopes of a trial continuing. EpiVaxs and Generexs earlier research on vaccine candidates for the H1N1 and SARS pandemics were halted largely due to funding limitations.

Still, the companies believe that this time around, it will not be as much of a barrier. If our trials are successful, Im sure that there will be opportunities to take a vaccine candidate even further, Porter said. There is government and other funding available, but there are many people trying to get it. We have many collaborations in place to move a COVID vaccine forward, so chances for success are very good.

Von Hofe highlighted the importance of reaching out to government officials, as well as voting for political candidates who will support vaccine research. Public interest is acute in the midst of a pandemic and then fades away, von Hofe said. But with the last 20 years having brought a handful of pandemics, now it is pretty clear that the regular emergence of pandemic or potentially pandemic viruses will not be going away, he added. Whatever happens with COVID-19, we will have learned a lot that will be applicable to whatever potential pandemic may come next; it is clear that we need to be better prepared.

While the timeline for this COVID-19 vaccines development remains indefinite, according to EpiVaxs website, were in the race to have the vaccines in clinical trials by the fall, Porter said.

See the original post:
Providence-based EpiVax collaborates on ongoing research for a COVID-19 vaccine - The Brown Daily Herald

Cuban Biotechnology develops 15 projects to face the pandemic – Tehran Times

Cuban scientists are working on 15 biotechnological projects to deal with COVID-19 that encompass diagnosis and treatment, officials from the BioCubaFarma entity announced.

Orlando Prez Rodrguez, director of Science and Innovation at BioCubaFarma, said that all clinical research and interventions have been duly authorized by Cuban regulatory entities and will be timely evaluated and reported to publicize Cuba's experience in this field.

He explained that 6 of the 15 projects are focused on treatment, the same number is prophylactic, two are diagnosticians and a medical team.

He added that the products focus on increasing people's innate immunity, reducing the viral load at the beginning of the disease and reducing the hyperinflammatory reaction in patients who develop it, especially in vulnerable groups (older adults or those with pathologies of antecedent).

As a sample of the responsiveness of Cuban Biotechnology, 9 of these projects are already in the phase of intervention trials or clinical studies and six are still in the research and development phase in laboratories, in addition to others in the design or early research.

He pointed out that in the treatment, in the initial stage Interferon Alpha 2B is used, for the management of the inflammatory reaction produced by COVID-19, the monoclonal antibody of the Immunoassay Center and a peptide from the Center for Genetic and Biotechnological Engineering are studied (CIGB).

Most products focus on the use of prophylactics, including nasal administration of interferon Alfa (to stimulate immunity), biomodulin-T (for those over 60 years of age), transfer factor (stimulates immunity in vulnerable groups), CIGB 2020 (immuno enhancer) and a vaccine candidate from the Finlay Institute (contains components of the Cuban meningitis vaccine).

Continue reading here:
Cuban Biotechnology develops 15 projects to face the pandemic - Tehran Times

Why genetics is key to the evolution of aquaculture – The Fish Site

Many species of fish and shellfish have been domesticated relatively recently compared with most livestock species, and so have diverse gene pools with major potential for selective breeding, according to a new review paper in Nature Reviews Genetics.

The development of tools to gain insight into the genetics of these species, and apply such tools for breeding and management, provides opportunities to release that potential, researchers say.

Most aquaculture species can produce many offspring, and large populations with improved genetics can be bred quickly for improved production performance.

The benefits may include improved growth, resistance to disease or robustness in diverse farming environments.

Farmed fish is on course to overtake wild fish as the main source of seafood, and consequently genetic tools and expertise are in high demand to increase the efficiency and sustainability of aquaculture systems, which currently rely mostly on unselected stocks.

Insight into the genomes of species can enable careful selection of a farming population with desirable traits, and monitoring genomic variation will help maintain genetic diversity as farm populations develop.

In the future, technologies such as genome editing could be used to introduce desirable traits, such as disease resistance, into farmed species, and surrogate breeding could be employed to support production of preferred species.

The review paper a collaboration between experts from Universities of Edinburgh, Exeter, Stirling, and Aberdeen is an output of the AquaLeap consortium project.

AquaLeap is funded by the Biotechnology and Biological Sciences Research Council, the Natural Environment Research Council and the Scottish Aquaculture Innovation Centre, in partnership with the Centre for Environment, Fisheries and Aquaculture Science, Hendrix Genetics, Xelect, The National Lobster Hatchery, Tethys oysters, and Otter Ferry SeaFish.

Environmental biologist Dr Eduarda Santos, from the University of Exeter, who is the co-author of the study, said: "The rapid expansion of aquaculture has contributed to increased food security across the globe, however, issues related to domestication of desired species and emergence of diseases, limit its further development.

"Genomics has the potential to offer solutions to many of these limitations by improving our knowledge of the genomes of cultured organisms, genetic selection, and better understanding of the dynamic interactions between genes and the environment, to maximise food production."

Dr Jamie Stevens, also from the University of Exeter and co-author added: "We only have to look at the example of Atlantic salmon to see the immense value of a sequenced genome to the relatively recent optimisation of a wild species for the aquaculture market.

"Similarly, we anticipate the delivery of a genome for other species, including the European lobster, will offer similar opportunities to develop molecular tools with which to rapidly increase the potential of lobster as an aquaculture species and improve the sustainability of its wild populations."

Professor Ross Houston, from the Roslin Institute, agreed, saying: "There is a timely opportunity to harness the potential of farmed aquatic species, to ensure food security for a growing population. Genomic selection and biotechnology can speed up this process, and recent developments in these fields will soon be translated to benefit aquaculture production for many of these species across the world."

Read more:
Why genetics is key to the evolution of aquaculture - The Fish Site

Global Biotechnology Market North America is expected to account for higher market share of more than… – Azizsalon News

Global Biotechnology Market is expected to grow at a CAGR of 14% to reach US$ XX million in 2026.

The growth is coupled with rising demand of modern and innovative technologies such as DNA sequencing, recombinant technology, fermentation, tissue engineering. Further, rising demand for food to meet the need of ever increasing population and scarce availability of non-renewable natural resources also expected to drive the biotechnology market. Application of Genetic engineering and Genetic Modification (GM) processes to agricultural food products also expected to drive the business growth. Furthermore, decreasing prices of DNA sequencing technologies will encourage R&D activities to better understand genetic variations and develop therapeutic solutions.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/10844

Moreover, development of novel techniques and their implementation by the organisation by collaborating with the other participants will drive the Global Biotechnology Market. Further, increasing demand for therapeutic and diagnostic solutions on principles of red biotechnology, DNA sequencing, and recombinant technology is expected to drive the Global Biotechnology Market through 2024. Increasing prevalence of diseases such as hepatitis B, cancer, and other orphan disorders is also expected to fuel demand in the forecast period.

In 2017, North America dominated the overall market. The market growth is driven by the increasing R&D investments relating to new drug discovery and development. U.S. held highest market in North America due to increasing level of per capita spending on healthcare than other countries and has a high growth rate amongst other countries. According to the estimates published by OECD Health Statistics in 2014, it has been estimated that in 2012, U.S. spent nearly 16.9% of its GDP towards healthcare expenditure, which is the highest. The fact supports the estimated share of Global Biotechnology Market.

Asia Pacific is expected to have higher growth rate in the forecast period owing to the presence of patient awareness, rapidly improving healthcare infrastructure, and rising healthcare expenditure levels in the emerging markets. Global Biotechnology Market include the developing economies of China and India.

In 2017, nanobiotechnology held the highest market share. The Global Biotechnology Market growth is driven by fermentation and cell-based assay segments owing to rising R&D initiatives by various biotechnological and pharmaceutical companies.

The objective of the report is to present comprehensive Global Biotechnology Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Biotechnology Market North America for Asia Pacific dynamics, structure by analyzing the market segments, and project the Global Biotechnology Market North America for Asia Pacific size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Biotechnology Market North America for Asia Pacific make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/10844

Market SegmentationGlobal Biotechnology Market, By Technologyo DNA Sequencingo Nanobiotechnologyo Tissue engineering and Regenerationo Fermentationo Cell Based Assayo PCR Technologyo Chromatography Marketo Others

Global Biotechnology Market, By Applicationso Healtho Food & Agricultureo Natural Resources & Environmento Industrial Processingo Bioinformaticso Others

The above data will be provided for following regions/countries from 2013-2024 (USD Million)

North Americao U.S.o Canada

Europeo Germanyo UKo Franceo Spaino Italy

Asia Pacifico Chinao Indiao Japano Australia

Latin Americao Argentinao Brazilo Mexico

Middle East and Africao South Africao Saudi Arabia

MAJOR TOC OF THE REPORT

Chapter One: Biotechnology Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Biotechnology Market Competition, by Players

Chapter Four: Global Biotechnology Market Size by Regions

Chapter Five: North America Biotechnology Revenue by Countries

Chapter Six: Europe Biotechnology Revenue by Countries

Chapter Seven: Asia-Pacific Biotechnology Revenue by Countries

Chapter Eight: South America Biotechnology Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Biotechnology by Countries

Chapter Ten: Global Biotechnology Market Segment by Type

Chapter Eleven: Global Biotechnology Market Segment by Application

Chapter Twelve: Global Biotechnology Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Biotechnology Market Report at:https://www.maximizemarketresearch.com/market-report/global-biotechnology-market/10844/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

More here:
Global Biotechnology Market North America is expected to account for higher market share of more than... - Azizsalon News

Investors should be cautious on the potential for Gilead’s drug Remdesivir, analysts say – CNBC

A new report from STAT News on Gilead's experimental drug Remdesivir serves as an encouraging update on the drug's potential to fight Covid-19, however analysts argue it's largely anecdotal and should be interpreted with caution.

Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS, both caused by coronaviruses.

According to the report from an ongoing phase three trial at a University of Chicago hospital, patients showing severe Covid-19 symptoms who were given the drug saw rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than one week.

Gilead commented that, "the totality of the data need to be analysed in order to draw any conclusions from the trial," in a statement to Reuters. A statement from the University of Chicago Medicine said that "drawing any conclusions at this point is premature and scientifically unsound."

Jefferies equity analyst Michael J. Yee published in a research note that this Chicago report provides an "incremental positive" but he assumes this significant short-term move in Gilead's share price will probably pull back a bit given eventual broader awareness that this is not the actual phase three data and that this is overdone in the near term.

JPMorgan biotechnology equity analysts wrote in a published research note Thursday that "this clinical trial experience appears to represent another encouraging, albeit largely anecdotal, data point for this high-profile drug candidate."

Meanwhile, the Barclays health-care team called the update "encouraging" but note that questions persist.

The report from the Chicago hospital comes amid mounting anecdotal evidence supporting the drug's potential effectiveness in treating the virus. Last week, the New England Journal of Medicine published an analysis showing that two thirds of a small group of severely ill patients saw their condition improve after taking the drug. These patients were given Remdesivir as part of a compassionate use program which allows doctors to provide patients with unauthorized treatments when no other treatment is available.

There was no control group in the University of Chicago study. As CNBC's Meg Tirrell has highlighted, this is not controlled clinical trial data it is a glimpse into what one of the sites that is running the trial is seeing.

The information reported by STAT News came from an internal discussion among faculty members at a University of Chicago hospital captured on video, it was not official data released by Gilead or any other trial leader.

Furthermore, this data comes from a single trial site. The Barclays health-care equity research team wrote: "While these data are encouraging, they are uncontrolled and from a single center."

Jefferies echoes this point: "Similar to the NEJM publication last week, yesterday's reports are based on one site and there is no placebo."

There is also debate around the severity of the patients included in the study. This data is part of an ongoing phase three trial of patients with severe Covid-19 symptoms. However, the patients were not intubated to start the study. Barclays adds that there will be debate around the patient population and how they compare to past cohorts.

"There's still a great deal we don't know, and thus we hesitate to put too much into the results generated at a single center without a control group," said JPMorgan.

"Fortunately, we don't have to wait long for a Phase 3 readout in severe patients."

Gilead expects results from its trials with patients with severe Covid-19 later this month. Data from its trials on patients with moderate symptoms is expected in May.

In addition to these two trials being run by Gilead, there are several others underway concurrently to evaluate Remdesivir, including a phase two trial run by the National Institute of Health which is an adaptive, randomized, double-blind, placebo-controlled trial.

Barclays adds that data from Gilead's clinical trials on severe cases due at the end of this month could support approval or expanded use authorization. A treatment is not going to end the pandemic. But it will provide a critical bridge to the ultimate panacea a vaccine.

CNBC's Berkeley Lovelace contributed to this article.

View post:
Investors should be cautious on the potential for Gilead's drug Remdesivir, analysts say - CNBC

Is Zai Lab Ltd (ZLAB) a Winner in the Biotechnology Industry? – InvestorsObserver

Zai Lab Ltd (ZLAB) is around the top of the Biotechnology industry according to InvestorsObserver. ZLAB received an overall rating of 69, which means that it scores higher than 69 percent of all stocks. Zai Lab Ltd also achieved a score of 73 in the Biotechnology industry, putting it above 73 percent of Biotechnology stocks. Biotechnology is ranked 8 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 69 means the stock is more attractive than 69 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Zai Lab Ltd (ZLAB) stock is down -6.63% while the S&P 500 has risen 0.14% as of 2:18 PM on Friday, May 22. ZLAB is down -$4.49 from the previous closing price of $67.75 on volume of 243,127 shares. Over the past year the S&P 500 is higher by 4.62% while ZLAB has risen 136.22%. ZLAB lost -$3.03 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read more:
Is Zai Lab Ltd (ZLAB) a Winner in the Biotechnology Industry? - InvestorsObserver

A coming bio revolution is poised to change the world – Axios

Increasingly inexpensive genetic sequencing and engineering tools could upend everything from health care to fuel.

Why it matters: This bio revolution could lead to a world that is more sustainable and even extend human lifespans. But its full extent is dependent on social acceptance and carries serious risks as well.

What's happening: The scientific reaction to COVID-19 illustrates the rapid change in the biological sciences, says Michael Chui, a partner at McKinsey Global Institute (MGI). "For SARS-CoV-2, it took a matter of weeks between identifying the new disease and sequencing it, compared to months for the original SARS virus."

But the response to COVID-19 only scratches the surface of what the bio revolution may make possible.

How it works: The chief driver of these changes is the rapid drop in cost of the tools that enable us to understand and increasingly manipulate the stuff of life, including in our own bodies.

The catch: Because biology is far more regulated than the field of artificial intelligence, the speed of the bio revolution will depend not just on science, but on public attitudes. The MGI report estimates 70% of the total impact could hinge on consumer, societal, and regulatory acceptance.

The bottom line: AI gets much of the attention, but advances in biotechnology are poised to be just as momentous. Put those two fields together and they will transform the world.

Read more:
A coming bio revolution is poised to change the world - Axios

Nautilus Biotechnology Raises $76 Million in Series B Funding to Be the First to Quantify the Human Proteome – Yahoo Finance

Vulcan Capital-led investment will enable Nautilus to bring a next-generation, single-molecule proteomics platform to market

Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, today announced it has raised $76 million in an oversubscribed Series B offering that closed on Monday, May 18, 2020. Nautilus total funding now exceeds $100 million. The Nautilus platform will deliver single-molecule sensitivity more quickly, more completely, and less expensively than is possible with existing technologies. This deeper, richer understanding of proteins will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and speed the adoption of personalized and predictive medicine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200521005020/en/

Nautilus Biotechnology founders Sujal Patel and Parag Mallick (Photo: Business Wire)

The funding round was led by Vulcan Capital, the multi-billion-dollar investment arm of Vulcan Inc., the company founded by Microsoft co-founder and philanthropist Paul G. Allen. In addition to Vulcan, Perceptive Advisors, Bezos Expeditions, and Defy Partners were new investors in the Series B offering. Previous investors AME Cloud Ventures, Andreessen Horowitz, Bolt, and Madrona Venture Group also participated in the round. The capital will be used to accelerate development of Nautilus proprietary proteomics platform and the expansion of scientific and engineering staff across a variety of levels and disciplines.

Nautilus was co-founded in 2016 by Sujal Patel, founder and CEO of Isilon Systems, a publicly-traded company that sold to EMC in 2010 for $2.6B, and Parag Mallick, PhD, Associate Professor of Radiology at Stanford University and a member of BioX, Stanford's pioneering interdisciplinary biosciences institute, and the Canary Center for Cancer Early Detection. The leadership team combines its entrepreneurial and research backgrounds to solve the challenge of more easily and completely quantifying the proteins that drive every aspect of human physiology. That limitation has impeded scientific and pharmaceutical R&D and Nautilus platform will enable a more comprehensive understanding of cellular and organismic biology.

"Existing proteomics technologies are slow, expensive, incomplete, and lack the sensitivity to deliver deep and meaningful insight into biological processes," said Nautilus co-founder and CEO, Sujal Patel. "Bringing together Parags breakthrough science with my deep understanding of large-scale IT has enabled us to approach the problem in a fundamentally new, more holistic way. Our value derives from a unique, interdisciplinary combination of biochemistry, computer science, and substantial business experience."

"The potential of proteomics has not been fully realized because of the limitations of current analysis methods," said Lee Hartwell, PhD, President and Director Emeritus of the Fred Hutchinson Cancer Research Center, 2001 co-recipient of the Nobel Prize in Physiology and Medicine, and member of Nautilus Scientific Advisory Board. "A greater resolution of the proteome will make it possible for the entire scientific and pharma R&D communities to undertake a wider range of high-value scientific inquiries, thereby accelerating both their research and the benefits that can accrue to human health."

Story continues

"Advancing scientific research and technology is at our core," said Stuart Nagae, Director of Venture Capital at Vulcan Capital. "With over a decade of experience investing in biotech and proteomics innovation, we believe that a reimagining of proteomics is long overdue. Nautilus has put together a special team with the vision, creativity, and experience to achieve that breakthrough, and execute on their vision."

ABOUT NAUTILUS BIOTECHNOLOGY

Based in San Carlos, CA and Seattle, WA, Nautilus is a biotechnology company whose proteomics platform will deliver superior sensitivity far more quickly, more completely, and less expensively than is currently possible. By breaking through the limitations of existing technologies, and effectively democratizing proteomics, Nautilus will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and usher in a new era of personalized and predictive medicine. Find Nautilus online: http://www.nautilus.bio

ABOUT VULCAN CAPITAL

Vulcan Capital is the multi-billion-dollar investment arm of Vulcan Inc., the company founded by Microsoft co-founder and philanthropist Paul G. Allen. Vulcan Capital focuses on generating long-term value appreciation across a portfolio, which spans diverse industry sectors and investment asset classes, ranging from early-stage venture investments to public equity value investing, leveraged buyouts, acquisitions, special situations and fixed income. Vulcan Capital was formed in 2003 and is headquartered in Seattle with additional offices in Palo Alto and Singapore.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005020/en/

Contacts

Nautilus Biotechnologypress@nautilus.bio

Kerry WalkerWalker Communicationskerry@walkercomms.com

See the rest here:
Nautilus Biotechnology Raises $76 Million in Series B Funding to Be the First to Quantify the Human Proteome - Yahoo Finance

BIO Appoints a Physician-Scientist as New President and CEO – Business Wire

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) the worlds largest science and public advocacy organization, representing 1,000 members announced today that Michelle McMurry-Heath, MD, PhD, will become the organizations next President and CEO on June 1, succeeding former Rep. Jim Greenwood, who has led the organization since 2005.

McMurry-Heath has served in numerous senior leadership roles at Johnson & Johnson (J&J) since 2014. Most recently, as Vice President of External Innovation and Global Leader for Regulatory Science, she led a team of 900 employees charting the evidence generation and regulatory strategy across J&Js medical device companies, specializing in using cutting-edge tools and innovative methods to bring new breakthroughs to patients.

We are living and working through a period in human history when scientific leadership and knowledge are crucial for our organization, our nation and the world, said BIO Chairman Dr. Jeremy Levin, CEO of Ovid Therapeutics. The biotechnology industry is humanitys great hope to speed medical breakthroughs to patients in record time to treat and prevent COVID-19 disease. With her exemplary scientific background, proven federal health policy leadership and track record of driving scientific progress to benefit patients, Michelle is the right person at the right time to lead BIO and the biotech sector into a new future. We welcome her to this new role and are excited to support her efforts to help shape the future of biotechnology. And as Michelle takes over, on behalf of the Board of Directors of BIO, I want to thank Jim Greenwood. Jim is a towering figure and has facilitated immense contributions to patients lives, innovation, our industry and our nation. We owe him a debt of gratitude and look forward to his next steps. I am proud to have worked with him.

As these clarifying times have shown, society will rise or fall on the ingenuity of our scientists, the vibrancy of our innovative ecosystem, and the personal courage of the men and women working day and night to bring cures to patients, food to tables and relief to our environment, McMurry-Heath said. I want scientists, clinicians and innovators to hold their heads high knowing they are addressing the most important issues we face today. BIO represents these everyday heroes and sheroes, and I couldnt be prouder for this opportunity to support their work and shout their message from the rooftop.

Prior to her work at J&J, McMurry-Heath served on the Obama administrations Science Transition Team before being appointed to a scientific leadership role at the U.S. Food and Drug Administrations (FDA) Center for Devices and Radiological Health from 2010 to 2014. During her tenure at FDA, McMurry-Heath was a driving force at the agency, specifically tasked with devising strategies to incorporate the patient perspective into the decision-making process and identifying opportunities for patients to collaborate with innovators.

McMurry-Heath, a Harvard-educated former senior FDA official, is a physician and a molecular immunologist who became the first African-American to graduate from the Duke Medical Scientist Training Program. She served as the founding director of the Aspen Institutes Health Biomedical Science and Society Policy Program focused on broadening access to personalized medicine and bolstering international preparedness for pandemic disease threats.

McMurry-Heath served as a science and technology policy fellow at the American Association for the Advancement of Science. She was also a Robert Wood Johnson Foundation Health and Society Scholar and led health and science policy on Capitol Hill for Senator Joe Lieberman, where she drafted legislation to protect the country from biological attacks. Additionally, she oversaw health policy for the Senators 2004 presidential campaign.

Science matters, now more than ever, Greenwood said. Michelles record of scientific leadership commands attention and respect among policymakers across the world. Michelle has been at the forefront of turning legislative victories into real-world realities for patients whose lives depend on biomedical innovation. Her experience as an innovator, a doer and a bipartisan collaborator will be great assets to BIO and the companies who depend on us to advocate on their behalf. I look forward to handing over BIO to her on June 1st. She will be a great leader.

McMurry-Heath will become just the third leader of BIO since the trade groups 1993 founding. Greenwood, a former six-term Pennsylvania Congressman, became the second leader in BIOs existence following the retirement of founding President Carl Feldbaum, former chief of staff to Senator Arlen Specter (R-PA). Under Greenwoods leadership, BIO has tripled in size. The organization hosts the worlds largest annual biotechnology convention, attracting tens of thousands of individuals from over 70 countries. BIO will hold its 2020 conference (BIO Digital) from June 8 to 12.

In March, BIO launched the Coronavirus Collaboration Initiative, an unprecedented effort among industry to share resources and capabilities to speed the development and delivery of COVID-19 diagnostics, therapeutics and ultimately a vaccine. Many smaller biotech companies have partnered with large biopharmaceutical companies to achieve R&D and manufacturing synergies during the pandemic.

Read more:
BIO Appoints a Physician-Scientist as New President and CEO - Business Wire

Global Biotechnology Algae Cultivation Process (Micro Algae) Market 2020 by Company, Regions, Type and Application, Forecast to 2026 – News Distinct

A research report on the Global Biotechnology Algae Cultivation Process (Micro Algae) Market delivers complete analysis regarding the size, trends, market share, and growth prospects. In addition, the report includes market volume with an exact opinion offered in the report. This research report assesses the market growth rate and the industry value depending on the growth such as driving factors, market dynamics, and other associated data. The information provided in this report is integrated based on the trends, latest industry news, as well as opportunities. The Biotechnology Algae Cultivation Process (Micro Algae) market report is major compilation of major information with respect to the overall competitor data of this market. Likewise, the information is an inclusive of the number of regions where the global Biotechnology Algae Cultivation Process (Micro Algae) industry has fruitfully gained the position. This research report delivers a broad assessment of the Biotechnology Algae Cultivation Process (Micro Algae) market. The global Biotechnology Algae Cultivation Process (Micro Algae) market report is prepared with the detailed verifiable projections, and historical data about the Biotechnology Algae Cultivation Process (Micro Algae) market size.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4421821

Moreover, the report also includes a full market analysis and supplier landscape with the help of PESTEL and SWOT analysis of the leading service providers. In addition, the projections offered in this report have been derived with the help of proven research assumptions as well as methodologies. By doing so, the Biotechnology Algae Cultivation Process (Micro Algae) research study offers collection of information and analysis for each facet of the Biotechnology Algae Cultivation Process (Micro Algae) industry such as technology, regional markets, applications, and types. The report has been made through the primary research interviews, complete surveys, as well as observations, and secondary research. Likewise, the Biotechnology Algae Cultivation Process (Micro Algae) market report delivers major illustrations and presentations about the market which integrates graphs, pie charts, and charts and offers the precise percentage of the different strategies implemented by the major providers in the global Biotechnology Algae Cultivation Process (Micro Algae) market. This report delivers a separate analysis of the foremost trends in the accessible market, regulations and mandates, micro & macroeconomic indicators are also included in this report.

Top Players:

CellanaEcodunaAlgenol BiofuelsSolix BiofuelsSapphire EnergySolazymeSeambioticLGemCyanotechDENSOMialgaeNeoalgae

Browse the complete report @ https://www.orbisresearch.com/reports/index/global-biotechnology-algae-cultivation-process-micro-algae-market-size-status-and-forecast-2020-2026

By doing so, the study forecast the attractiveness of each major segment over the prediction period. The global Biotechnology Algae Cultivation Process (Micro Algae) market study extensively features a complete quantitative and qualitative evaluation by studying data collected from various market experts and industry participants in the market value chain. The report also integrates the various market conditions around the globe such as pricing structure, product profit, demand, supply, production, capacity, as well as market growth structure. In addition, this study provides important data about the investment return data, SWOT analysis, and investment feasibility analysis.

Types:

Euglenophyta (Euglenoids)Chrysophyta (Golden-Brown Algae and Diatoms)Pyrrophyta (Fire Algae)Chlorophyta (Green Algae)Rhodophyta (Red Algae)Paeophyta (Brown Algae)Xanthophyta (Yellow-Green Algae)Others

Applications:

FoodFertilizer and AgarPollution ControlEnergy Production

In addition, the number of business tactics aids the Biotechnology Algae Cultivation Process (Micro Algae) market players to give competition to the other players in the market while recognizing the significant growth prospects. Likewise, the research report includes significant information regarding the market segmentation which is designed by primary and secondary research techniques. It also offers a complete data analysis about the current trends which have developed and are expected to become one of the strongest Biotechnology Algae Cultivation Process (Micro Algae) market forces into coming future. In addition to this, the Biotechnology Algae Cultivation Process (Micro Algae) report provides the extensive analysis of the market restraints that are responsible for hampering the Biotechnology Algae Cultivation Process (Micro Algae) market growth along with the report also offers a comprehensive description of each and every aspects and its influence on the keyword market.

If enquiry before buying this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4421821

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Read the rest here:
Global Biotechnology Algae Cultivation Process (Micro Algae) Market 2020 by Company, Regions, Type and Application, Forecast to 2026 - News Distinct

B.R.A.I.N. Biotechnology Research And Information Network AG: Change in the Management Board of BRAI – PharmiWeb.com

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Personnel07.05.2020 / 08:00 The issuer is solely responsible for the content of this announcement.

Change in the Management Board of BRAIN AG

Chief Financial Officer Manfred Bender is leaving the biotechnology company at the end of the current financial year. Lukas Linnig to become the new CFO.

Zwingenberg, Germany07 May 2020

The biotechnology company B.R.A.I.N. Biotechnology Research and Information Network AG announces that Chief Financial Officer Manfred Bender will leave the company at his own request on 30 September 2020. Mr Bender will take on a new assignment and has therefore asked the Supervisory Board to terminate his contract prematurely. The Supervisory Board has complied with this request.

The new Chief Financial Officer will be Lukas Linnig, the current Head of Finance, Controlling and Legal. Linnig has worked for the company since April 2017 and he previously advised BRAIN as a consultant during the IPO.

Dr Georg Kellinghusen, Chairman of the Supervisory Board, says: "We regret Mr Bender's decision, but we respect it. We thank him for his great contribution and commitment to BRAIN AG. With Lukas Linnig, we have found a successor who knows the company extremely well. There is sufficient time for an orderly transition until Mr Bender leaves the company."

Adriaan Moelker, CEO BRAIN AG, commented: "Lukas Linnig has proven that he has all the skills for a strong CFO. I am very pleased to have him on the management board and I am confident that with Lukas' appointment we are taking an important step in building a strong future-orientated team."

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the "Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at http://www.brain-biotech.com.

B.R.A.I.N.Biotechnology ResearchAnd Information Network AGDarmstdter Str. 34-3664673 ZwingenbergGermanywww.brain-biotech.com

Contact Investor RelationsMichael SchneidersPhone: +49-(0)6251-9331-86Mobil: +49-(0)172 7957319Email: mis@brain-biotech.com

Media ContactDr. Stephanie KonleManaging Associate Corporate CommunicationsPhone: +49-(0)6251-9331-70Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)

07.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Follow this link:
B.R.A.I.N. Biotechnology Research And Information Network AG: Change in the Management Board of BRAI - PharmiWeb.com